DeckTherapeutics is pioneering the new field of “acute omega-3 fatty acid therapeutics”. Emulsions of our proprietary semi-synthetic omega-3 compounds are administered intravenously and exert immediate effect on multiple molecular pathways critical for controlling cellular apoptosis and necrosis.

More than a decade of in vitro and in vivo studies at Dr. Deckelbaum’s laboratory at Columbia University indicate that the emulsions are particularly effective as neuroprotectants after hypoxic-ischemic or hypoxia-reperfusion events in adults or neonates, but the emulsions have also shown great potential in tissue protection after acute myocardial infarction, acute renal injury, spinal cord injury as well as in complex metabolic dysfunctions such as non-alcoholic steatohepatitis.